Patent classifications
B82Y5/00
Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease.
Electrochemical detection nanostructure, systems, and uses thereof
Described herein are DNA-nanostructures that can be used in an assay to detect and/or quantify an analyte of interest. Aspects of the DNA-nanostructure can include a single DNA molecule composed of hairpin structural motifs, an anchor recognition moiety, and a signal moiety, where the anchor recognition moiety and the signal moiety are in effective proximity to each other such that the tethered diffusion of the signal molecule can be altered based upon binding status of the anchor recognition moiety. Also described herein are methods of making and using the DNA-nanostructures.
Modified Nano-Silica Gel for Improving Symptoms Caused by Bacteria and Viruses and Preparation Method and Application Thereof
A modified nano-silica gel for improving symptoms caused by bacteria and viruses and a preparation method and an application thereof. The patented nano-silica gel is modified by a modified compound to obtain a modified nano-silica gel to effectively reduce an amount of toxins excreted by sows, thereby providing piglets with a safe environment that is more suitable for survival. The modified nano-silica gel of the invention comprises: a nano-silica gel with a content of 13.0-92.3 wt %; a modified compound with a content of 0.15-3.50 wt %, the modified compound is an organic compound, a weight ratio of the nano-silica gel to the modified compound is 620:1 to 3.5:1; and water with a formula of H.sub.2O and a content of 7.5-86.8 wt %; the nano-silica gel, the modified compound and the water are stirred and mixed at a temperature of 40-80° C. to prepare the modified nano-silica gel.
A Novel formulation for rapid wound healing and control of infection
The present invention is a formulation of organic and non-organic components for rapid wound healing and control of infection. The components of the present invention i.e. the formulation are an antimicrobial agent, an antioxidant, a cell proliferation inducing factor and an organic component responsible for matrix formation. Adding these four components in pre-determined proportions, formulations can be made for gels, liquid solution and biodegradable scaffolds which are safe and gives a synergistic effect.
A Novel formulation for rapid wound healing and control of infection
The present invention is a formulation of organic and non-organic components for rapid wound healing and control of infection. The components of the present invention i.e. the formulation are an antimicrobial agent, an antioxidant, a cell proliferation inducing factor and an organic component responsible for matrix formation. Adding these four components in pre-determined proportions, formulations can be made for gels, liquid solution and biodegradable scaffolds which are safe and gives a synergistic effect.
Immunogenic composition forming a vaccine, and a method for its manufacture
An immunogenic composition forming a vaccine includes a nanoparticle delivery system comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a nucleic acid encoding a protein from a coronavirus.
Immunogenic composition forming a vaccine, and a method for its manufacture
An immunogenic composition forming a vaccine includes a nanoparticle delivery system comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a nucleic acid encoding a protein from a coronavirus.
Icariin nano-pharmaceutical formulation
A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.
Icariin nano-pharmaceutical formulation
A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.
Complexes for delivery of antigenic peptides
The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.